Intracellular mechanisms of TRAIL and its role in cancer therapy.
Srivastava
R K
RK
Department of Pharmaceutical Sciences, University of Maryland-School of Pharmacy, Greenebaum Cancer Center, 20 North Pine Street, Baltimore, Maryland 21201, USA.
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D051017:Apoptosis Regulatory Proteins; D006801:Humans; D008024:Ligands; D008562:Membrane Glycoproteins / Q000502:physiology* / Q000627:therapeutic use; D009369:Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology* / Q000627:therapeutic use; D019014:fas Receptor / Q000502:physiology
D051017:Apoptosis Regulatory Proteins; D008024:Ligands; D008562:Membrane Glycoproteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor